Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The world’s biggest medtech expects great things from its new surgical robot, but its best shot at leading a market with a new product remains renal denervation.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
The failure of gosuranemab could bode ill for Abbvie’s ABBV-8E12 in particular.
The data were statistically significant, but the market had been hoping for more.
Acumen is the latest player to take aim at amyloid, but competition is fierce.
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
But this week three transactions did squeak through.
But with Derm Assist available free, how will the company make money?
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
A test that tracks response to therapy is useful, but approval and reimbursement will be key.
A small molecule for alpha-1 antitrypsin deficiency faces a key clinical test, and its chances of success aren’t good.